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Objectives: To determine whether inflammation in the gut
associated immune system is activated in rheumatoid arthritis
(RA). The expression of chemokine receptor- (CCR4, CCR5)
and cytokine- (interleukin (IL)2, IL10, interferon c (IFNc),
tumour necrosis factor a (TNFa), and transforming growth
factor b (TGFb)) specific mRNA in intestinal biopsy samples
from patients with RA was examined.
Methods: Duodenal biopsy samples from 13 patients with
RA and 15 control subjects were studied. The mRNA
expression of CCR4, CCR5, IL2, IL10, IFNc, TNFa, and
TGFb in intestinal biopsy samples was demonstrated by real
time quantitative reverse transcriptase-polymerase chain
reaction.
Results: The mRNA expression of CCR4, CCR5, and IL10 in
intestinal biopsy samples was increased in patients with RA in
comparison with control subjects (p = 0.001, p = 0.046,
p = 0.019). No difference in the expression levels of IL2,
IFNc, TNFa, or TGFb was seen between patients with RA and
controls.
Conclusions: The increased intestinal mRNA expression of
IL10, CCR5, and CCR4 suggests that gut associated immune
cells are activated in patients with RA.
G
ut lesions have been found in patients with rheumatic
diseases, while peripheral arthritis is occasionally
found in patients with gastrointestinal diseases.1 2
Increased permeability, raised numbers of inflammatory
cells, and increased HLA-DR expression in the gut have been
reported in patients with rheumatoid arthritis (RA).3 4 Occult
intestinal inflammation, which may be related to non-
steroidal anti-inflammatory drug treatment or may be
associated with disease, occurs in about 67% of patients
with RA,5 but markers of gut inflammation are not restricted
to the use of non-steroidal anti-inflammatory drugs.4 Also, an
increased expression of the gut associated surface molecule,
aEb7, which is expressed on.95% of intestinal intraepithelial
lymphocytes and on 40% of lamina propria lymphocytes, is
found on synovial fluid derived T cells in comparison with
peripheral blood lymphocytes in patients with RA.6 This
suggests an accumulation of lymphocytes derived from the
gut in the inflamed joints.7
The expression profile of cytokines and chemokine
receptors in tissue reflects the stage of inflammation and
may also be an indicator of the functional phenotype of
immune cells. T cells are divided into type 1 and type 2 cells
supporting cytotoxic or humoral immune response, respec-
tively. Type 1 response has been associated with interferon c
(IFNc) and interleukin (IL)2 secretion and expression of
CCR5 and CXCR3, whereas type 2 response has been
associated with expression of CCD3, CCR4, CCR8, and
secretion of IL4, IL5, and IL13. In humans, this dichotomy
between type 1 and 2 cells is, however, not so clear.7
To date only a few reports have been published dealing
with the profile of cytokines and chemokine receptors
expressed in the gut of patients with rheumatic diseases,8
and, as far as we know, no such studies exist on patients with
RA. Therefore, we studied the mRNA expression of CCR4,
CCR5, IL2, IL10, IFNc, tumour necrosis factor a (TNFa), and
transforming growth factor b (TGFb) in duodenal biopsy
samples from patients with RA.
PATIENTS AND METHODS
Patients
Duodenal gut biopsy samples were obtained from 13 patients
with RA (12 women, 1 man, mean age 59, range 39–84 years)
and 15 control subjects (10 women, 5 men, mean age 50,
range 30–76 years) in whom gastroscopy was performed with
clinical indications. In patients with RA the endoscopy was
performed in the presence of abdominal pain or if bleeding
was suspected. In the controls the endoscopy was performed
in the presence of abdominal pain or symptoms of reflux.
Table 1 presents the characteristics of patients and controls.
In addition to routine samples, three additional biopsy
samples of duodenum were obtained in 0.9% NaCl. The
biopsy samples were frozen at –70 C̊ for later analysis. In all
the cases, the duodenum was normal both by inspection and
by histology. The patients and controls gave their written
informed consent. The study protocol was approved by the
ethics committee of Helsinki University Central Hospital.
Real time reverse transcriptase-polymerase chain
reaction (RT-PCR)
The mRNA expression of cytokines and chemokine receptors
was demonstrated by real time RT-PCR from mucosal
samples. Total RNA (tRNA) was extracted from frozen biopsy
samples, stored at 270 C̊, by RNA Total Gen Elute
Mammalian RNA kit. Reverse transcription reaction was
carried out in a final volume of 75 ml using TaqMan reverse
transcription reagents (Applied Biosystems, Foster City, CA,
USA). The reaction mix contained 106RT buffer, 5.5 mg
MgCl2, 500 mmol/l of each dNTP, 2.5 mM random hexamers,
0.4 U/ml RNase inhibitor, and 10 ng/ml template RNA. The
solution was treated with 0.01 U/ml DNAase (Boehringer
Mannheim) for 30 minutes at 37 C̊, followed by heat
inactivation at 75 C̊ for 5 minutes and cooling to 25 C̊.
1.25 U/ml multiscribe reverse transcriptase enzyme was added
and the mixture was subjected to 48 C̊ for 30 minutes and
inactivated at 95 C̊ for 5 minutes. The cDNA was stored at
220 C̊ until use.
Real time PCR was performed with an automated
fluorometer, ABI Prism 7700 Sequence Detection System
Abbreviations: IL, interleukin; INFc, interferon c; RA, rheumatoid
arthritis; RT-PCR, reverse transcriptase-polymerase chain reaction;
TGFb, transforming growth factor b; TNFa, tumour necrosis factor a
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(Applied Biosystems), and TaqMan PDAR (predeveloped
assay reagents) primers/probes. The PDAR primers/probes
for TGFb (catalogue No 4327054F), TNFa (catalogue No
4327055F), IL10 (catalogue No 4327043F), IFNc (catalogue
No 4327052F), IL2 (catalogue No 4327036F), CCR4 (catalo-
gue No 4324583F), and CCR5 (catalogue No 4324596F) were
used. Ribosomal 18S (catalogue No 4310893E) was used as
endogenous control. The PCR reactions were run in triplicate
wells with 50 ng (for target gene) or 5 ng (for endogenous
control) of template cDNA in a final volume of 25 ml.
Amplification conditions were 2 minutes at 50 C̊, 10 minutes
at 95 C̊, and 50 cycles of 15 seconds at 95 C̊ and 60 seconds at
60 C̊.
The expression of each cytokine was measured also from a
home-made calibrator sample, which was prepared by
stimulating peripheral blood mononuclear cells from a
healthy subject with phytohaemagglutinin for 48 hours.
We used the comparative Ct method to measure the gene
transcription in samples. The Ct of 18S was subtracted from
the cytokine Ct to give the DCt value. The DCt of the analysed
sample was then subtracted from the DCt of the calibrator.
This difference is called the DDCt value. The results are
expressed as relative units based on calculation of 22DDCt,
which gives the relative amount of cytokine normalised to
endogenous control (18S) and compared with calibrator.
Statistics
A comparison of variables between the groups was carried
out with the Mann-Whitney test. A p value ,0.05 was
considered significant.
RESULTS
Real time quantitative RT-PCR
Figure 1 shows the expression of chemokine receptors and
cytokine IL10 mRNA in duodenal biopsy samples. The levels
of CCR4, CCR5, and IL10 mRNA in intestinal biopsy samples
were higher in patients with RA than in control subjects
(median relative units being 1 v 0.2 and p=0.001 for CCR4,
median 61 v 15, p=0.046 for CCR5, and median 1 v 0.3,
p=0.019 for IL10). No differences were seen in the IFNc, IL2,









Indication Endoscopic findings Stomach Duodenum
RA1 75 28 MTX+SSZ/2 Anaemia Mild gastritis Mild chronic inflammation
(antrum, corpus)
Normal





RA3 83 50 2/+ Heartburn, abdominal pain Gastric atrophy, antral
intestinal metaplasia
Atrophy and intestinal metaplasia
in antrum
Normal
RA4 63 17 LEF/2 Abdominal pain Large prepyloric ulcer Normal Normal
RA5 43 2 MTX/2 Anaemia Normal Normal Normal




RA7 55 7 MTX/+ Abdominal pain Duodenogastric reflux Mild chronic inflammation
(corpus)
Normal
RA8 50 10 LEF/+ Anaemia Hiatus hernia Normal Normal
RA9 56 14 MTX+SSZ/+ Abdominal pain, vomiting Normal Normal Normal
RA10 47 24 2/2 Abdominal pain Mild antrum gastritis Mild chronic inflammation
(corpus)
Normal
RA11 42 ,1 2/2 Diarrhoea Normal Normal Normal
RA12 39 4 SSZ+HCQ/2 Abdominal pain, anaemia Mild corpus gastritis Intestinal metaplasia, atrophy
in corpus, mild chronic
inflammation (corpus, antrum)
Normal
RA13 84 4 HCQ/+ Anaemia Angular ulcer Severe chronic inflammation
(angulus), severe intestinal
metaplasia and atrophy in
antrum
Normal
CTRL1 39 Abdominal pain Normal Normal Normal
CTRL2 53 Barrett’s oesophagus
(control)




CTRL3 43 Heartburn Mild chronic gastritis Mild chronic gastritis (antrum,




CTRL4 70 Barrett’s oesophagus (control) Normal Normal Normal
CTRL5 65 Barrett’s oesophagus
(control)





CTRL6 39 Diarrhoea Normal Normal Normal
CTRL7 53 Hypoalbuminaemia Erosions in antrum, corpus Moderate chronic inflammation
(antrum, corpus), Hp+
Normal
CTRL8 56 Reflux (control) Haematomatous cystic
polyps in corpus
Normal Normal












CTRL11 36 Suspected submucous
tumour (control)
Normal Mild intestinal metaplasia (antrum) Normal
CTRL12 30 Abdominal discomfort Normal Normal Normal
CTRL13 75 Problems in swallowing Hiatus hernia Normal Normal
CTRL14 30 Abdominal pain Suspected antral polyps Normal Normal
CTRL15 38 Heartburn Oesophagitis Gastric histology normal,
candida oesophagitis
Normal
RA, rheumatoid arthritis; CTRL, control subject; DMARD, disease modifying antirheumatic drug; PRED, prednisone; MTX, methotrexate; SSZ, sulfasalazine; HCQ, hydroxychloroquine; LEF,
leflunomide; Hp+, Helicobacter pylori positive at histology.
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TGFb, or TNFa mRNA levels in patients with RA when
compared with controls.5
DISCUSSION
We found increased expression of IL10, CCR4, and CCR5
mRNA in duodenal biopsy samples from patients with RA.
Normal human small intestinal lymphocytes express CCR5
and CXCR3, so called type 1 immune response associated
chemokine receptors, and lack the expression of CXCR1,
CXCR2, CCR1, CCR3, CCR4, and CCR7.9
CCR5 is expressed on a greater proportion of gut-homing
peripheral blood lymphocytes than on those thought to home
to extraintestinal sites in normal intestine,9 which may
suggest that CCR5 is an important receptor for selective
recruitment of lymphocytes to the intestine. Furthermore, the
expression of RANTES, a ligand of CCR5, is increased in the
inflamed intestine.10 The expression of CCR5 has been
associated with type 1 immune response and with secretion
of IFNc, but despite findings related to CCR5 expression, we
did not find increased expression of IFNc or IL2 mRNA levels
in our patients with RA. We observed highest levels of IFNc
mRNA expression in RA, but there was great variation in
both patient and control groups.
CCR4 has been associated with type 2 immune response,
but CCR4 positive cells are not exclusively type 2 restricted
and are also expressed at target tissues in immunological
disease with a type 1 deviation.7 Expression of CCR4 is found
in the inflamed intestine, but it is not expressed on intestinal
T cells of healthy subjects.9 In an animal model of chronic
intestinal inflammation, IL10 deficient mice expressed CCR4,
CCR2, and CCR6 mRNA locally in the inflamed mucosa.11
Another study showed that CCR4 was absent from the lung
and skin of normal subjects, but was present in the lung of
atopic patients,12 supporting the induction of CCR4 in
inflamed mucosa. The increased CCR4 mRNA expression in
the intestine of patients with RA can be considered as a
marker of inflammation, while it is too speculative to draw
conclusions of the T1/T2 polarisation of the mucosal immune
response in RA. IL10 has a dual role in the inflammatory
process as it has both anti-inflammatory and proinflamma-
tory potential.
Both CCR4 and CCR5 are also expressed on monocyte
lineage cells. Thus, possibly, our findings reflect activation of
the innate immune system. Interestingly, IL10, which is
secreted by monocytes and T cells, was also found to be
increased in the gut of patients with RA. The role of IL10 in
the intestinal homoeostasis is shown by studies on IL10
deficient mice, which develop chronic inflammation in the
intestine with no obvious inflammatory lesions elsewhere.13
However, the anti-inflammatory role of IL10 has recently
been questioned in RA. In patients with RA high IL10
concentrations have been detected in the serum and synovial
fluid.14 15 B lymphocytes are also potent producers of IL10.
IL10 has been shown to correlate with serum rheumatoid
factor titres and in vitro levels of spontaneous IgM RF
production,14 suggesting that activation of IL10 secretion is
linked to inflammatory activity in RA. Also, an increased
number of IL10 expressing CD3+ CD8+ T cells in the ileal
lamina propria lymphocytes have been reported in patients
with spondyloarthropathy.8
In conclusion, patients with RA have evidence of inflam-
matory activation in the gut, which may play a role in the
pathogenesis of the disease.
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